| Addressing cell death regulation |
|
| Mapatumumab (HGS1012) + sorafenib vs sorafenib |
Monoclonal antibody against TRAIL-R1 |
II |
NCT01258608 |
|
|
| Tigatuzumab (CS1008) + sorafenib vs sorafenib |
Monoclonal antibody against TRAIL-R2 |
II |
NCT01033240 |
|
|
| Resminostat (4SC-201) + sorafenib vs sorafenib |
HDAC inhibitor |
II |
NCT00943449 |
|
|
| XIAP antisense (AEG35156) + sorafenib vs sorafenib |
XIAP antisense |
I–II |
NCT00882869 |
[133] |
|
| Addressing overactivation of survival pathways |
|
| BIIB022 + sorafenib vs sorafenib |
Monoclonal antibody against IGF-1R |
I |
NCT00956436 |
[7] |
|
| Cixutumumab (IMC-A12) + sorafenib vs sorafenib |
Monoclonal antibody against IGF-1R |
II |
NCT00906373 |
[7] |
|
| AZD6244 + sorafenib vs sorafenib |
MEK1/2 inhibitor |
I–II |
NCT01029418 |
|
|
| Refametinib (BAY86-9766) + sorafenib vs sorafenib |
MEK1/2 inhibitor |
II |
NCT01915602 |
|
|
| Refametinib (BAY86-9766) + sorafenib vs sorafenib |
MEK1/2 inhibitor |
II |
NCT01204177 |
[147] |
|
| Erlotinib + sorafenib vs sorafenib |
EGFR/HER1 inhibitor |
III |
NCT00901901 |
[140] |
|
| Tivantinib (ARQ197) |
c-Met inhibitor |
II |
NCT00988741 |
[145] |
|
| Tivantinib (ARQ197) |
c-Met inhibitor |
III |
NCT02029157 |
|
|
| Onartuzumab vs sorafenib |
c-Met inhibitor |
I |
NCT01897038 |
|
|
| MSC2156119J |
c-Met inhibitor |
I–II |
NCT02115373 |
|
|
| Golvatinib (E7050) + sorafenib vs sorafenib |
c-Met and VEGFR2 inhibitor |
I–II |
NCT01271504 |
|
|
| Everolimus (RAD001) + sorafenib vs sorafenib |
mTOR inhibitor |
I |
NCT00828594 |
|
|
| Addressing the TGF-β pathway |
|
| LY2157299 + sorafenib vs sorafenib |
TGFBR1 inhibitor |
II |
NCT02178358 |
[157] |
